Business Context and Reporting Period
Company: Protalix Biotherapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: Protalix is a biopharmaceutical company developing recombinant therapeutic proteins using its proprietary plant cell-based expression system, ProCellEx. The company's lead product candidate is taliglucerase alfa for the treatment of Gaucher disease. In November 2009, Protalix entered into an exclusive license and supply agreement with Pfizer Inc. for the worldwide development and commercialization of taliglucerase alfa (excluding Israel), retaining rights to commercialize the drug in Israel.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Revenues | $6.6 million | $0.4 million |
| Cost of Revenues | $4.4 million | $3.6 million |
| Gross Profit | $6.9 million | ($3.2 million) |
| Research & Development Expenses (Net) | $30.0 million | $21.6 million |
| General & Administrative Expenses | $6.9 million | $7.1 million |
| Net Loss | ($29.0 million) | ($31.4 million) |
| Cash and Cash Equivalents (Year End) | $35.9 million | $81.3 million |
| Total Assets | $64.7 million | $98.7 million |
| Total Liabilities | $76.1 million | $82.8 million |
| Shareholders' Equity (Capital Deficiency) | ($11.3 million) | $15.9 million |
Note: The company recorded $4.6 million in income from its share of the collaboration agreement with Pfizer in 2010, primarily from sales to the Ministry of Health of Brazil.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased significantly from $0.4 million in 2009 to $6.6 million in 2010. This was driven by the amortization of the $65 million upfront and milestone payments received from Pfizer (recognized over a 14-year period) and $2.0 million in product sales to Pfizer.
- Operating Loss: Despite revenue growth, the company reported a net loss of $29.0 million in 2010 compared to $31.4 million in 2009. The reduction in net loss was offset by a substantial increase in Research and Development (R&D) expenses, which rose 38% to $30.0 million due to expanded access programs and personnel costs.
- Liquidity Position: Cash and cash equivalents decreased by approximately $45.4 million, from $81.3 million to $35.9 million. Net cash used in operating activities was $38.5 million, primarily due to the net loss and an increase in accounts receivable.
- Equity Status: The company moved from positive shareholders' equity of $15.9 million in 2009 to a capital deficiency of $11.3 million in 2010 due to the accumulated deficit.
Guidance, Outlook, and Risks
Regulatory Outlook:
- taliglucerase alfa: The FDA accepted the New Drug Application (NDA) in July 2010 and assigned a Prescription Drug User Fee Act (PDUFA) date of February 25, 2011. Marketing applications were also submitted to the Israeli Ministry of Health, the European Medicines Agency (EMEA), and Brazil's ANVISA.
- Other Pipeline: The company is advancing PRX-102 (Fabry disease), PRX-105 (biodefense), and pr-antiTNF (autoimmune diseases). An IND for PRX-102 is expected within 12 months.
Management Commentary:
- Management believes current cash resources and anticipated regulatory milestone payments from Pfizer are sufficient to fund operations for at least the next 12 months.
- The company plans to spend approximately $35 million over the next 12 months to build an internal sales force for Israel, expand manufacturing capacity, and advance pipeline candidates.
- A $25 million manufacturing facility expansion is planned for completion in 2012 to serve approximately 50% of the Gaucher disease patient population.
Risks and Contingencies:
- Regulatory Approval: Failure to obtain FDA or foreign regulatory approval for taliglucerase alfa would severely impact the business.
- Liquidity: The company has no significant product revenues outside of the Pfizer collaboration and will require additional capital to continue operations beyond the next 12 months.
- Manufacturing: Reliance on third parties for final fill and finish steps and the need to maintain cGMP compliance pose operational risks.
- Intellectual Property: The company relies on patents for its ProCellEx system and product candidates; infringement claims or failure to secure patents could be detrimental.
Key Facts for Investor Verification
- PDUFA Date: Verify the FDA's decision on the taliglucerase alfa NDA by the February 25, 2011 deadline.
- Cash Runway: Confirm the company's ability to fund operations for the next 12 months given the $35.9 million cash balance and high burn rate.
- Pfizer Collaboration: Monitor the status of the $50 million in potential regulatory milestone payments and the profitability of the Brazil supply agreement.
- Manufacturing Expansion: Track progress on the $25 million facility expansion required to meet commercial demand.
- Israeli Tax Benefits: Verify continued eligibility for "Approved Enterprise" tax exemptions, which are critical to the company's financial structure.